Media Newsroom of
CorMatrix Cardiovascular Inc.
CorMatrix delivers biomaterial devices that harness the body's innate ability to repair damaged cardiac and vascular tissues. CorMatrix ECM remodels over time into healthy, vascularized tissue serving as a superior alternative to synthetic materials.
CorMatrix Cardiovascular Announces Sale of First Pipeline Assets
CorMatrix Cardiovascular, Inc. (www.cormatrix.com), a leader in cardiovascular tissue engineering, today announces the sale of its pipeline first-to-market regenerative devices to Aziyo Biologics. CorMatrix, a developer of extracellular matrix cardiovascular devices, has sold over 160,000 devices to the market since…
CorMatrix® Cardiovascular Inc. Secures USPTO Allowance of Two (2) Additional Patent Claim Sets for Its CanGaroo® ECM® Envelope
CorMatrix® Cardiovascular Incorporated, a company specializing in Extracellular Matrix (ECM®) Regenerative technology announced today that the U.S. Patent and Trademark Office has officially allowed two (2) additional claim sets under U.S. Patent Nos. 14/833,354 and 14/833,340 for its CorMatrix® CanGaroo®…
CorMatrix Cardiovascular Secures Fifty-Six (56) Patents in 2016 Expanding Patent Protect for Extracellular Matrix (ECM®) Based Implantable Devices
CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) a leading developer of biomaterial compositions and medical devices for regenerative medicine, today announced the issuance of 56 patents in 2016. The ongoing expansion of this patent portfolio continues to support the Company’s development of novel…